Evidence map›Paper›PMID 28616743›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2018

The long-term survival of stage IV gastric cancer patients with conversion therapy.

Kazuya Yamaguchi, Kazuhiro Yoshida, Toshiyuki Tanahashi, Takao Takahashi, Nobuhisa Matsuhashi, Yoshihiro Tanaka, Kazuaki Tanabe, Hideki Ohdan

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 115 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04886193 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study

TypeinterventionalSponsorGuangdong Provincial Hospital of Traditional Chinese MedicineRan2021 to 2023Enrolled20ConditionsChemotherapy, Gastric CancerArmsFLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
NCT06413212 recruitingnot on this mapstarted 2023, after this paper: background citation

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

TypeobservationalSponsorLiu HuangRan2023 to 2025Enrolled55ConditionsLung Cancer, Breast Cancer, Gastric Cancer, Colorectal CancerArmsPatient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Comparison of minimally invasive surgery and open surgery following chemotherapy for cStage IVb gastric cancer: a multicenter retrospective cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  10. Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  11. Article
  12. Article
  13. Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kazuya YamaguchiDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan. kyoshida@gifu-u.ac.jp.
Toshiyuki TanahashiDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Takao TakahashiDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Yoshihiro TanakaDepartment of Surgical Oncology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Kazuaki TanabeDivision of Frontier Medical Science, Department of Surgery, Graduate School of Biomedical Sciences Hiroshima University, Hiroshima, Japan.
Hideki OhdanDivision of Frontier Medical Science, Department of Surgery, Graduate School of Biomedical Sciences Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA retrospective study was performed to clarify the role of conversion therapy (surgery with a prospect of R0 resection performed in initially unresectable metastatic cancer that responded to the chemotherapy) in stage IV gastric cancer (GC). PATIENTS AND

methodsWe treated 259 stage IV GC patients with systemic chemotherapy at Gifu and Hiroshima University Hospitals between 2001-2013. Of these, 84 patients who were subsequently treated by surgery were classified into four categories according to our previously published classification of stage IV GC, and short- and long-term outcomes were analyzed.

resultsSurgery was performed in 84 patients, of which 7 were performed following the neoadjuvant chemotherapy, whereas the other 77 that excluded neoadjuvant chemotherapy cases were considered the conversion therapy. The postoperative mortality and morbidity were comparable with those reported clinical trials. The MSTs of the patients with/without surgery for each category were 28.3/5.8 months for category 1, 30.5/11.0 months for category 2, 31.0/18.5 months for category 3 and 24.7/10.0 months for category 4. The MST of the R0 resected patients (41.3 months) was far better than that of the R1-2 resected patients (21.2 months). The MSTs of the patients with R0/R1-2 resection were 56.2/16.3 months for category 2, 33.3/29.6 months for category 3 and 40.7/17.8 months for category 4.

conclusionThere were long-term survivors who underwent conversion therapy for stage IV GC. Adequate selection of stage IV GC patients for conversion therapy may be an important role for the surgical oncologist in the new era.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleGastrectomyHumansKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesStomach NeoplasmsTreatment OutcomeAdjuvant surgeryChemotherapyConversion therapyGastric cancerMetastatic gastric cancer

Identifiers

PMID28616743
PMCPMC5846815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.